Aastrom Biosciences Inc news

   Watch this stock
Showing stories 1 - 10 of about 20   

Articles published

ASTM 0.550 -0.010 (-1.79%)
price chart
Curis Inc. (NASDAQ:CRIS) up by 5.33%, Aastrom Biosciences Inc (NASDAQ ...
Curis, Inc. (NASDAQ:CRIS) is by gaining 5.33% in Monday's trading and closed at $4.35, after starting its day with a value of $4.13.
Aastrom Biosciences Reports First Quarter 2013 Financial Results
ANN ARBOR, May 08, 2013 (GLOBE NEWSWIRE via COMTEX) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today ...
Aastrom Biosciences (ASTM) Announces Quarterly Earnings, Beats ...  Zolmax
Related articles »  
Stocks Down For The Day: Ambac Financial Group Inc. (OTCMKTS:ABKFQ ...
Aastrom Biosciences Inc (NASDAQ:ASTM) fell 10.87% at $0.615 after trading 771,408 shares. The company is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic ...
Related articles »  
Aastrom Biosciences's Neutral Rating Reaffirmed at Zacks (ASTM)
Aastrom Biosciences logo Zacks reaffirmed their neutral rating on shares of Aastrom Biosciences (NASDAQ: ASTM) in a research note released on Thursday morning, Stock Ratings Network reports.
Related articles »  
Regenerative Medicine's Time Has Come
The big loser recently was Aastrom Biosciences, Inc. (ASTM). In March ASTM shares lost 50% after the company said that it will stop enrollment in and end the Phase 3 Revive clinical trial for patients with critical limb ischemia, or restricted blood ...
Esperion plans IPO to get drug to market
He had been president and CEO of Ann Arbor-based Aastrom Biosciences Inc. (Nasdaq: ASTM). While at Aastrom, Mayleben raised $75 million in equity capital and got several of its stem-cell therapies into ongoing FDA trials.
Related articles »  
US/Canada daily earnings hits & misses May 8 - 1700 ET
... 0.11 0.16 0.05 3.9 3.9 0.0 AASTROM BIOSCIENCES INC Q1 BIOTECHNOLOGY USD -0.19 -0.15 0.04 0.0 0.0 0.0 ABSOLUTE SOFTWARE CORPOR Q3 UNDESIGNATED TECHNOLOGY USD 0.01 -0.01 -0.02 20.1 20.9 0.8 ACELRX PHARMACEUTICALS I ...
Related articles »  
Neuralstem (NYSE:CUR) Declares Wider Net Loss in First Quarter � CUR, STEM ...
StemCells Inc (NASDAQ:STEM) fell -2.11% to settle at $1.86, Aastrom Biosciences Inc (NASDAQ:ASTM) moved up +7.14% to end at $0.600 while Charles River Laboratories (NYSE:CRL) jumped +1.35% to finish at $44.31 on Tuesday.
DIARY-NON S&P WEEK AHEAD
N/A N/A N/A 08 May 11:00 Q1 2013 ArQule, Inc. -0.11 7 -0.08 08 May AMC Q1 2013 Aastrom Biosciences -0.19 7 -0.25 08 May AMC Q1 2013 Atlas Energy, L.P.
Related articles »  
Stem Cells: Invest At Your Own Peril
As such, I trimmed the roster down to only one company, Osiris Therapeutics, Inc. That said, I believe OSIR is simply the "best of the worst", and is still hampered by the many problems inherent in the sector.